Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson s Disease
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The gr...